- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Ray Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation
The designation for RTx-015 in retinitis pigmentosa marks a significant milestone for the company's optogenetic therapy development.
Apr. 1, 2026 at 4:54pm
Got story updates? Submit your updates here. ›
Ray Therapeutics, a clinical-stage biopharmaceutical company focused on optogenetic therapies for retinal degenerative diseases, has announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to its lead candidate, RTx-015, for the treatment of retinitis pigmentosa.
Why it matters
The RMAT designation is an important regulatory pathway that can expedite the development and review of regenerative medicine therapies, potentially providing faster access to innovative treatments for patients with vision-threatening conditions like retinitis pigmentosa.
The details
RTx-015 is an optogenetic therapy that uses light-sensing proteins to restore light sensitivity in retinal cells, potentially improving vision for those with advanced retinal degeneration. The RMAT designation recognizes the therapy's potential to address an unmet medical need and will allow for increased engagement with the FDA to optimize the clinical development program.
- Ray Therapeutics announced the RMAT designation on April 1, 2026.
The players
Ray Therapeutics
A clinical-stage biopharmaceutical company pioneering optogenetic therapies for retinal degenerative diseases.
RTx-015
Ray Therapeutics' lead candidate, an optogenetic therapy for the treatment of retinitis pigmentosa.
U.S. Food and Drug Administration (FDA)
The regulatory agency that granted the Regenerative Medicine Advanced Therapy (RMAT) designation to RTx-015.
What’s next
With the RMAT designation, Ray Therapeutics will work closely with the FDA to optimize the clinical development program for RTx-015 and potentially accelerate the path to regulatory approval.
The takeaway
The RMAT designation for RTx-015 represents a significant milestone for Ray Therapeutics and its efforts to develop innovative optogenetic therapies that could restore vision and improve the quality of life for patients with retinal degenerative diseases.
